MARKSANS2024-04-012024-06-30 MARKSANS2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member MARKSANS2024-06-30 MARKSANS2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524404 MARKSANS NOTLISTED Marksans Pharma Limited Equity 2024-04-01 2025-03-31 2024-08-13 2024-07-31 INR Millions First quarter 18:30:00 19:30:00 2024-08-13 2024-08-13 Not applicable Single segment Manufacturing & Marketing of Pharmaceutical Formulations 2024-04-01 2024-06-30 Unaudited Standalone 2545270000.00 81520000.00 2626790000.00 1161160000.00 309930000.00 -66890000.00 231930000.00 2830000.00 68360000.00 496480000.00 2203800000.00 422990000.00 0.00 422990000.00 103580000.00 -740000.00 102840000.00 0.00 320150000.00 0.00 0.00 0.00 0.00 320150000.00 710000.00 320860000.00 320860000.00 0.00 453160000.00 1 0.71 0.71 0.00 0.00 0.71 0.71 1. The unaudited standalone financial results for the quarter ended 30 June 2024 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13 August 2024. The Statutory Auditors of the Company has carried out limited review on the above results in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 ( the Regulation ), as ammended and expressed an unmodified conclusion. 2. The unaudited standalone financial results of the company have been prepared in accordance with the recognition and measurement principals laid down in the Indian Accounting Standard 34 'Interim Financial Reporting', prescribed underSection 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principals generally accepted in India and in terms of the Regulation. 3. The figures for the quarter ended March 31, 2024 represent the derived figures between the audited figures in respect of the full financial year ended March 31, 2024 and the unaudited published year-to-date figures up to December 31, 2023, being the date of the end of third quarter of the financial year, which were subjected to a limited review by the statutory auditor of the Company. 4. The Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments'. 5. The above unaudited standalone financials results of the Company are available on the Company's Website (www.marksanspharma.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed. Other expenses 496480000.00 Remeasurements of the net defined benefit liabilities/assets, 950000.00 950000.00 240000.00 0.00